Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors

Sean Tan; Ella Spear; Nikhita Sane; Adam J Nelson; Nitesh Nerlekar; Eva Segelov; Stephen J Nicholls

doi:10.1038/s41371-023-00831-z

Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors

J Hum Hypertens. 2023 Nov;37(11):1043-1046. doi: 10.1038/s41371-023-00831-z. Epub 2023 Apr 19.

Authors

Sean Tan^{1

2}, Ella Spear³, Nikhita Sane³, Adam J Nelson^{4

3}, Nitesh Nerlekar^{4

3}, Eva Segelov⁵, Stephen J Nicholls^{4

3}

Affiliations

¹ Victorian Heart Institute, Monash University, Melbourne, VIC, Australia. [email protected].
² Monash Heart, Monash Health, Melbourne, VIC, Australia. [email protected].
³ Monash Heart, Monash Health, Melbourne, VIC, Australia.
⁴ Victorian Heart Institute, Monash University, Melbourne, VIC, Australia.
⁵ Monash University, Melbourne, VIC, Australia.

Abstract

Immune checkpoint inhibitors (ICI) are cancer therapies that have been associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). Blood pressure (BP) measurements are routinely performed during day oncology center visits for administration of ICI therapy but are often not assessed temporally to screen and monitor hypertension, which could independently increase the risk of ASCVD in cancer survivorship. This study reports the feasibility of using serial BP measurements from routine visits to day oncology center to diagnose and monitor hypertension control in cancer patients receiving ICIs.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Atherosclerosis*
Blood Pressure
Humans
Hypertension* / diagnosis
Hypertension* / drug therapy
Immune Checkpoint Inhibitors / adverse effects
Neoplasms* / drug therapy

Substances

Immune Checkpoint Inhibitors